Quick Takeaways
- Dechra has received FDA approval for CosACTHen (cosyntropin injection), the first and only FDA-approved cosyntropin specifically indicated for evaluating adrenal function in dogs. The therapy is designed to support diagnosis, confirmation, and monitoring of endocrine disorders including Cushing’s Disease and Addison’s Disease in canine patients
- CosACTHen will be used as part of ACTH stimulation testing, a key diagnostic method for assessing adrenocortical function and monitoring dogs receiving Vetoryl (trilostane). The product is available as a 0.25 mg/ml solution in single-use vials and can be administered through intravenous or intramuscular injection with cortisol levels measured before and after stimulation testing
- The approval further strengthens Dechra’s endocrinology portfolio and specialty veterinary care focus, particularly in canine endocrine disorders where the company reported more than 1,200 Cushing’s-related case consults over the past year. CosACTHen is refrigerated for ready-to-use emergency access and will be supported through Dechra’s Veterinary Technical Services resources for clinicians
Why It Matters?
CosACTHen gives Dechra a differentiated diagnostic anchor in canine endocrinology and should strengthen its existing Cushing’s/Addison’s franchise built around Vetoryl.
As the first and only FDA‑approved cosyntropin specifically for dogs, it will likely shift ACTH stimulation testing away from human ACTH products and compounded specials toward a branded, ready‑to‑use veterinary vial, supporting premium pricing, tighter Dechra–clinic relationships, and more consistent monitoring of the growing population of dogs on trilostane therapy.
Source: PRnewswire
